Mizuho Medy Co.,Ltd. (TYO:4595)

Market Cap	29.54B
Revenue (ttm)	11.34B
Net Income (ttm)	3.58B
Shares Out	19.05M
EPS (ttm)	167.06
PE Ratio	9.28
Forward PE	n/a
Dividend	100.00 (6.45%)
Ex-Dividend Date	Jun 27, 2025

Volume	146,700
Average Volume	59,415
Open	1,533.00
Previous Close	1,539.00
Day's Range	1,531.00 - 1,563.00
52-Week Range	1,341.00 - 1,824.00
Beta	0.48
RSI	71.61
Earnings Date	May 9, 2025

About Mizuho Medy

Mizuho Medy Co.,Ltd. researches and develops, manufactures, and sells in-vitro diagnostic products and related scientific and technical information services primarily in Japan. The company provides immunoassay test products, such as influenza virus kits; RS virus and human metapneumovirus antigen test kits; streptococcus pneumoniae antigen and legionella antigen test kits; mycoplasma pneumoniae antigen test kits; adenovirus antigen test kits; rotavirus and adenovirus antigen test kits; norovirus antigen test kits; group a streptococcal antigen ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1977
• Employees: 187
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4595

Financial Performance

In 2024, Mizuho Medy's revenue was 11.43 billion, an increase of 4.00% compared to the previous year's 10.99 billion. Earnings were 3.77 billion, a decrease of -0.03%.